Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of RO4917838 for persistent predominant negative symptoms of schizophrenia
NL-OMON37510Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bitopertin in schizophrenia (3 arms), sponsored by Roche. Primary endpoints: Change in PANSS negative symptom factor score at 24 weeks and Incidence of adverse events. Planned start Aug 2012; status: withdrawn.
02
Drugs
bitopertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON37510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37510.